Discover
Verzenio (abemaciclib) / Eli LillyVerzenio (abemaciclib) significantly reduced the risk of cancer returning in people with high risk HR+, HER2- early breast cancer (PRNewswire) - Jun 16, 2020 - P3, N=4580; monarchE (NCT03155997); Sponsor: Eli Lilly and Company; "Eli Lilly and Company…announced Verzenio® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) has met the primary endpoint of invasive disease-free survival (IDFS), significantly decreasing the risk of breast cancer recurrence or death compared to standard adjuvant ET alone. These results are from a pre-planned interim analysis of the Phase 3 monarchE study – making Verzenio the only CDK4 & 6 inhibitor to demonstrate a statistically significant reduction in the risk of cancer recurrence for people with high risk hormone receptor-positive…(HER2-) early breast cancer…Lilly plans to present these data at a medical meeting later this year…' We look forward to submitting these data to regulatory authorities before the end of 2020'…The monarchE trial will continue through the completion date, estimated for June 2027."
